The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...

IRVINE, Calif. (KABC) -- A diagnosis of ALS is devastating. The rare neurological disease, also known as "Lou Gehrig's disease" attacks nerve cells responsible for controlling voluntary muscle ...

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

Every year roughly 1,000 Canadians are diagnosed with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). Some 4,000 Canadians are currently living with the disease. There are few ...

Amyotrophic lateral sclerosis (ALS) remains one of the most devastating and biologically elusive neurodegenerative diseases. Despite decades of research, its underlying mechanisms are still not fully ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...